Of interest is that CML LSCs were characterized by a specific expression of a surface expression of dipeptidylpeptidase-IV, which can cleave CXCL12 and reduce its biological activities [70]. The gene discussed is CXCL12; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.